We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 60

Most ad complaints involving personalhealth care products upheld in India
  • Shook Hardy & Bacon LLP
  • India
  • July 10 2014

The most recent data released by the Advertising Standard Council of India (ASCI) show that the largest percentage of complaints upheld (95--46


India to ban PET packaging for certain pharmaceuticals
  • Shook Hardy & Bacon LLP
  • India, USA
  • January 9 2014

Citing increasing concerns about potential adverse health effects, the Indian Health Ministry is reportedly considering prohibiting the use of


Indian Supreme Court assesses care or cure properties of product in tariff dispute
  • Shook Hardy & Bacon LLP
  • India
  • August 29 2013

The Indian Supreme Court has affirmed lower tribunal rulings that Moisturex is a medicament used for its curative properties and, as such, is


FDA inspection finds CGMP violations at Bangalore facility
  • Shook Hardy & Bacon LLP
  • India, USA
  • June 26 2014

The U.S. Food and Drug Administration (FDA) has issued a warning letter to the president and CEO of Apotex, Inc., claiming that the agency's


EU agency will reinstate Ranbaxy’s GMP certificate
  • Shook Hardy & Bacon LLP
  • European Union, India
  • June 12 2014

The European Medicines Agency (EMA) has reportedly concluded its investigation of alleged non-compliance with good manufacturing practice (GMP) at


Skin lightening products stir controversy worldwide
  • Shook Hardy & Bacon LLP
  • India, Japan, Malaysia, Philippines
  • June 26 2014

From allegations about mercury-laden skin lightening creams in the Philippines to new draft guidelines in India about advertising such products in a


India holds out among countries requiring transparency in industry payments
  • Shook Hardy & Bacon LLP
  • India
  • June 20 2013

According to a news source, while many countries have instituted disclosure obligations on health-care companies, often pharmaceutical and


Ranbaxy loses FDA approval for two generics
  • Shook Hardy & Bacon LLP
  • India, USA
  • November 13 2014

According to a statement that Ranbaxy Laboratories Ltd. provided to the Bombay Stock Exchange Website, the U.S. Food and Drug Administration (FDA


Cosmetics, personal care products purportedly linked to kids’ allergies
  • Shook Hardy & Bacon LLP
  • India
  • November 20 2014

A small study of households in India has purportedly associated higher levels of indoor pollutants, including household products, such as cosmetics


India to consider ban on importing animal-tested cosmetics
  • Shook Hardy & Bacon LLP
  • India, USA
  • January 9 2014

Following the June 2013 decision to prohibit the testing of domestically produced cosmetics and their ingredients on animals (details about which